Scheduled Event - 2 May 2024, 11 a.m.
View Source
Lords - Oral questions - Main Chamber
Assessment of NHS England London stating that “anyone with ovaries can get ovarian cancer” in a social media post rather than referring to "women"
MP: Baroness Hayter of Kentish Town

---

Departmental Publication (Policy and Engagement)
Department for Business and Trade

Apr. 18 2024

Source Page: The Smart Data Roadmap: action the government is taking in 2024 to 2025
Document: (PDF)

Found: A recent study, funded by Cancer Research UK found that analysis of loyalty card data , from two UK

---

---

Departmental Publication (Transparency)
Home Office

Apr. 12 2024

Source Page: Non-technical summaries granted in 2024
Document: Non-technical summaries: projects granted in 2024, January to March (PDF)

Found: Studying novel treatments for ovarian Cancer 669 80.

---

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Apr. 09 2024

Source Page: MHRA FOI performance data
Document: (Excel)

Found: you be able to advise whether MHRA are looking to approve mirvetuximab for use in platinum resistant ovarian

---

Non-Departmental Publication (Guidance and Regulation)
Medicines and Healthcare products Regulatory Agency

Apr. 04 2024

Source Page: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelines
Document: M3(R2) – Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (PDF)

Found: Pharmaceuticals under development for indications i n life-threatening or serious diseases (e.g., advanced cancer

---

Non-Departmental Publication (Guidance and Regulation)
Medicines and Healthcare products Regulatory Agency

Apr. 04 2024

Source Page: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelines
Document: S5(R3) – Revision of S5 Guidelines on Detection of Toxicity to Reproduction for Human Pharmaceuticals (PDF)

Found: Comparison of the intraperitoneal and intravenous routes of cisplatin administration in an advanced ovarian

---

Written Question

Ovarian Cancer: Diagnosis

Tuesday 2nd April 2024

Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether her Department plans to shorten the diagnostic pathway for ovarian cancer by allowing the CA125 blood test and ultrasound to be undertaken at the same time.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The Department is supporting NHS England in developing Best Practice Timed pathways, to support the ongoing improvement effort to shorten diagnosis pathways, reduce variation, improve patient experience of care, and meet the Faster Diagnosis Standard. This standard ensures patients are told they have cancer, or that cancer is ruled out, within 28 days of urgent cancer referral from general practice or screening service.

In March 2023, NHS England published guidance for local health and care systems to implement a timed gynaecological cancer diagnostic pathway, including for ovarian cancer. The gynaecological pathway ensures that at day zero, when presenting with symptoms, an ultrasound and a minimum data set is obtained, which includes a full blood count. For patients with suspected ovarian cancer, the minimum dataset should also include tumour marker CA125, with confirmation of suspicious features of ovarian cancer on ultrasound.

The guidance further ensures that patients with persistent abdominal symptoms, raised CA125, and a normal pelvic scan should be referred through the non-specific symptoms rapid diagnostic centre pathway. Women over 50 years old with elevated CA125 and palpable mass or ascites, or both, or with a previous ultrasound with risk of malignancy, should be referred straight to a computed tomography scan.

---

Written Question

Ovarian Cancer: Diagnosis

Thursday 28th March 2024

Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps she is taking to reduce regional variations in early diagnosis of ovarian cancer.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

Reducing inequalities and variation in cancer treatment is a priority for the Government, as is increasing early cancer diagnosis, as both are key contributors to reducing cancer health inequalities. The National Health Service is improving cancer pathways to get people diagnosed faster once referred, and is looking into alternative routes into the system, including non-specific symptom (NSS) pathways for patients who do not fit clearly into a single urgent cancer referral pathway, but who are at risk of being diagnosed with cancer. This will help support faster ovarian cancer diagnosis. 113 NSS pathways are currently operational, with more in development.

---

---